BR112015010276A2 - peptídeos miméticos - Google Patents
peptídeos miméticosInfo
- Publication number
- BR112015010276A2 BR112015010276A2 BR112015010276A BR112015010276A BR112015010276A2 BR 112015010276 A2 BR112015010276 A2 BR 112015010276A2 BR 112015010276 A BR112015010276 A BR 112015010276A BR 112015010276 A BR112015010276 A BR 112015010276A BR 112015010276 A2 BR112015010276 A2 BR 112015010276A2
- Authority
- BR
- Brazil
- Prior art keywords
- mimetic peptides
- methods
- diagnostic
- mimetic
- peptides
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000007592 Apolipoproteins Human genes 0.000 abstract 1
- 108010071619 Apolipoproteins Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12191474 | 2012-11-06 | ||
| PCT/IB2013/059948 WO2014072916A1 (en) | 2012-11-06 | 2013-11-06 | Mimetic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015010276A2 true BR112015010276A2 (pt) | 2019-10-15 |
Family
ID=47115623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015010276A BR112015010276A2 (pt) | 2012-11-06 | 2013-11-06 | peptídeos miméticos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10087234B2 (enExample) |
| EP (1) | EP2917234B1 (enExample) |
| JP (1) | JP6499967B2 (enExample) |
| KR (1) | KR102215175B1 (enExample) |
| CN (1) | CN104768970B (enExample) |
| BR (1) | BR112015010276A2 (enExample) |
| CA (1) | CA2888657C (enExample) |
| ES (1) | ES2859559T3 (enExample) |
| MX (1) | MX364626B (enExample) |
| RU (1) | RU2662973C2 (enExample) |
| WO (1) | WO2014072916A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL268093B2 (en) * | 2017-01-19 | 2024-07-01 | Us Health | Apoc-ii mimetic peptides |
| CA3096493A1 (en) | 2018-04-10 | 2019-10-17 | Sanofi-Aventis Deutschland Gmbh | Method for cleavage of solid phase-bound peptides from the solid phase |
| JP7332620B2 (ja) * | 2018-04-10 | 2023-08-23 | サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | キャップ付加を伴うリキシセナチドの合成 |
| CN108948158B (zh) * | 2018-07-21 | 2021-06-15 | 河南大学 | 四连接素模拟肽tnp及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| SE0103754L (sv) * | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| EP1706131A4 (en) * | 2003-12-15 | 2009-08-12 | Univ California | THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES |
| WO2007022248A2 (en) * | 2005-08-16 | 2007-02-22 | Sloan Kettering Institute For Cancer Research | Methods of detection of cancer using peptide profiles |
| JP2010530433A (ja) * | 2007-06-20 | 2010-09-09 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｐｏａ−１ペプチド模倣体 |
| US8957026B2 (en) * | 2010-09-22 | 2015-02-17 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| CA2834657A1 (en) * | 2011-04-29 | 2012-11-01 | Kinemed, Inc. | Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents |
-
2013
- 2013-11-06 RU RU2015121688A patent/RU2662973C2/ru active
- 2013-11-06 BR BR112015010276A patent/BR112015010276A2/pt not_active IP Right Cessation
- 2013-11-06 US US14/440,790 patent/US10087234B2/en active Active
- 2013-11-06 CN CN201380057907.5A patent/CN104768970B/zh not_active Expired - Fee Related
- 2013-11-06 ES ES13792995T patent/ES2859559T3/es active Active
- 2013-11-06 JP JP2015540267A patent/JP6499967B2/ja not_active Expired - Fee Related
- 2013-11-06 MX MX2015005761A patent/MX364626B/es active IP Right Grant
- 2013-11-06 WO PCT/IB2013/059948 patent/WO2014072916A1/en not_active Ceased
- 2013-11-06 EP EP13792995.6A patent/EP2917234B1/en active Active
- 2013-11-06 CA CA2888657A patent/CA2888657C/en active Active
- 2013-11-06 KR KR1020157013810A patent/KR102215175B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2917234A1 (en) | 2015-09-16 |
| RU2015121688A (ru) | 2016-12-27 |
| JP6499967B2 (ja) | 2019-04-10 |
| CA2888657C (en) | 2022-05-03 |
| KR102215175B1 (ko) | 2021-02-15 |
| JP2016505514A (ja) | 2016-02-25 |
| KR20150082350A (ko) | 2015-07-15 |
| MX2015005761A (es) | 2015-08-12 |
| CA2888657A1 (en) | 2014-05-15 |
| ES2859559T3 (es) | 2021-10-04 |
| US20150291682A1 (en) | 2015-10-15 |
| US10087234B2 (en) | 2018-10-02 |
| RU2662973C2 (ru) | 2018-07-31 |
| CN104768970B (zh) | 2019-11-15 |
| EP2917234B1 (en) | 2020-12-02 |
| CN104768970A (zh) | 2015-07-08 |
| WO2014072916A1 (en) | 2014-05-15 |
| MX364626B (es) | 2019-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014001994A1 (es) | Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido. | |
| MX386418B (es) | Composicion acida que comprende una ficocianina. | |
| CY1120390T1 (el) | Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων | |
| CL2014003171A1 (es) | Composicion liofilizada que comprende al menos una benzodiazepina de formula (i), al menos un excipiente higroscopico seleccionado de disacaridos y dextrano; metodo de preparacion de la composicion farmaceutica. | |
| MX2016017355A (es) | Lipido que comprende acido docosapentaenoico. | |
| BR112018010118A2 (pt) | inibidores de cxcr2 | |
| UY34218A (es) | MÉTODO DE DETECCIÓN DEL EVENTO DE SOJA pDAB9582.814.19.1 | |
| EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
| BR112017023516A2 (pt) | composição de polímero reforçado com fibra, e, artigo. | |
| MD20150062A2 (ro) | Compuşi antivirali | |
| BR122019002801B8 (pt) | Método para selecionar uma planta de milho e método para identificar uma planta de milho transformada | |
| BR112016001611A2 (pt) | Anticorpos multiespecíficos, anticorpos ativáveis multiespecíficos e métodos de utilização dos mesmos | |
| CL2016000190A1 (es) | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca. | |
| BR112016015105A2 (pt) | Conjugados var2csa-droga | |
| CL2014002225A1 (es) | Metodo para elaborar composicion enriquecida en inmunoglobulinas a partir de plasma que comprende co-precipitación de inmunoglobulinas y alfa-1-antitripsina (a1pi); metodo para tratar deficiencia inmune, enfermedad inflamatoria, enfermedad autoinmune o infección aguda. | |
| BR112015000072A2 (pt) | configuração de compósito. | |
| BR122021023230B8 (pt) | Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado | |
| BR112014027904A2 (pt) | compressor com movimento alternado. | |
| CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
| MX373239B (es) | Mejoras en o con relacion a compuestos organicos. | |
| BR112017021190A2 (pt) | composição farmacêutica e o uso da mesma | |
| EA201590503A1 (ru) | Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями | |
| BR112015011759A2 (pt) | composição simbiótica e uso da mesma | |
| EA201400940A1 (ru) | Способ получения медетомидина | |
| MX2016001384A (es) | Metodos para incrementar el volumen espiratorio forzado en pacientes asmaticos que usan benralizumab. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2799 DE 27/08/2024. |